Business Description
Hanmi Science Co Ltd
NAICS : 325412
SIC : 2834
214 Muha-ro Paltan-myeon, Gyeonggi-do, Hwaseong, KOR
Compare
Compare
Traded in other countries / regions
008930.Korea
Description
Hanmi Science Co Ltd is a Korea-based holding company. The company through its subsidiaries manufactures and distributes pharmaceutical products. The company offers prescription drugs such as neuropathic pain, obesity, epilepsy, lactobacillus intestinal supplement, oral care, hair growth, anti-inflammatory, schizophrenia, smoking cessation aid, diabetes, osteoporosis, antiemetic, vaginal contraceptive, expectorants, ophthalmic, immunosuppressant, prostatism, cancer, antitussives, vitamins and nutritional supplements, constipation, dermatology, among others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.25 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | 0.91 | |||||
| Interest Coverage | 133.04 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 8.08 | |||||
| Beneish M-Score | -2.12 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.3 | |||||
| 3-Year EBITDA Growth Rate | 31.9 | |||||
| 3-Year EPS without NRI Growth Rate | 33.6 | |||||
| 3-Year FCF Growth Rate | 96.1 | |||||
| 3-Year Book Growth Rate | 1.9 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.81 | |||||
| 9-Day RSI | 54.83 | |||||
| 14-Day RSI | 52.84 | |||||
| 6-1 Month Momentum % | -18.52 | |||||
| 12-1 Month Momentum % | -46.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1 | |||||
| Quick Ratio | 0.55 | |||||
| Cash Ratio | 0.06 | |||||
| Days Inventory | 45.04 | |||||
| Days Sales Outstanding | 33.13 | |||||
| Days Payable | 47.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.5 | |||||
| Dividend Payout Ratio | 0.28 | |||||
| 3-Year Dividend Growth Rate | 2 | |||||
| Forward Dividend Yield % | 0.5 | |||||
| 5-Year Yield-on-Cost % | 0.5 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 14.03 | |||||
| Operating Margin % | 3.21 | |||||
| Net Margin % | 4.89 | |||||
| ROE % | 7.08 | |||||
| ROA % | 5.13 | |||||
| ROIC % | 3.36 | |||||
| ROC (Joel Greenblatt) % | 90.05 | |||||
| ROCE % | 7.87 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 57.98 | |||||
| PE Ratio without NRI | 56.31 | |||||
| Shiller PE Ratio | 63.44 | |||||
| Price-to-Owner-Earnings | 80.32 | |||||
| PEG Ratio | 3.97 | |||||
| PS Ratio | 2.83 | |||||
| PB Ratio | 4.02 | |||||
| Price-to-Tangible-Book | 4.06 | |||||
| Price-to-Free-Cash-Flow | 311.61 | |||||
| Price-to-Operating-Cash-Flow | 239.87 | |||||
| EV-to-EBIT | 49.98 | |||||
| EV-to-EBITDA | 45.9 | |||||
| EV-to-Revenue | 2.88 | |||||
| EV-to-FCF | 307.3 | |||||
| Price-to-Projected-FCF | 4.18 | |||||
| Price-to-Median-PS-Value | 0.46 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.32 | |||||
| Price-to-Graham-Number | 3.24 | |||||
| Earnings Yield (Greenblatt) % | 2 | |||||
| Forward Rate of Return (Yacktman) % | 19.97 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₩) | 1,005,827.934 | ||
| EPS (TTM) (₩) | 766.364 | ||
| Beta | 1.62 | ||
| Volatility % | 37.13 | ||
| 14-Day RSI | 52.84 | ||
| 14-Day ATR (₩) | 1165.275459 | ||
| 20-Day SMA (₩) | 41010 | ||
| 12-1 Month Momentum % | -46.25 | ||
| 52-Week Range (₩) | 37400 - 75686.274509 | ||
| Shares Outstanding (Mil) | 67.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hanmi Science Co Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||